Co-Authors
This is a "connection" page, showing publications co-authored by Kathleen Mazor and Mara Epstein.
Connection Strength
0.936
-
Fisher KA, Epstein MM, Nguyen N, Fouayzi H, Crawford S, Linas BP, Mazor KM. COVID-19 clinical trials: who is likely to participate and why? J Comp Eff Res. 2024 08; 13(8):e230181.
Score: 0.244
-
Casta?eda-Avila MA, Mazor KM, Lapane KL, Epstein MM. Patient and provider-level drivers of healthcare utilization related to a diagnosis of a precancerous condition: monoclonal gammopathy of undetermined significance (MGUS). Cancer Causes Control. 2023 May; 34(5):449-457.
Score: 0.221
-
Casta?eda-Avila MA, Lapane KL, Person SD, Zhou Y, Gurwitz J, Mazor KM, Epstein MM. Multi-trajectory models of serum biomarkers among patients with monoclonal gammopathy of undetermined significance. Hematol Oncol. 2022 Aug; 40(3):409-416.
Score: 0.207
-
Casta?eda-Avila MA, Lapane KL, Person SD, Jesdale BM, Zhou Y, Mazor KM, Epstein MM. Differences in Hospital, Emergency Room and Outpatient Visits Among Adults With and Without Monoclonal Gammopathy of Undetermined Significance. Cancer Control. 2022 Jan-Dec; 29:10732748221126936.
Score: 0.204
-
Fisher KA, Mazor KM, Epstein MM, Goldthwait L, Abu Ghazaleh H, Zhou Y, Crawford S, Marathe J, Linas BP. Long COVID awareness and receipt of medical care: a survey among populations at risk for disparities. Front Public Health. 2024; 12:1360341.
Score: 0.060